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 The median of packed RBCs consumed in the perioperative period decreased from two (2013-2015) to zero (2016-2017);  
 The length of stay at PICU followed the same pattern, prior to PBM the patients had a median stay of 3 days at PICU, 
 after PBM implementation they only spend 1.85 days at the unit; 
 The implementation of the PBM program allowed for a substantial decrease of packed RBC transfusion and length of PICU admission. 
 
 
 
 
 
Scoliosis affects 2-4% of children; 
The aim of Pediatric Scoliosis Surgery (PSS) is to avoid worsening of respiratory and cardiac function; 
This surgery is associated with high rates of packed red blood cells (RBC) transfusion (bleeding risk is greater in neuromuscular etiology); 
Patient Blood Management (PBM) programs have been introduced to minimize the use of blood transfusion; 
In January 2016, at our institution, a Pediatric PBM program was adopted in pediatric patients undergoing PSS. 
 
AIM of our study: Evaluate the efficiency of our PBM program. 
INTRODUCTION 
2013-2015 Begining of 2016 2016-2017 
Before implementation of PBM (Control Group) 
No. of patients 59  
 
Introduction of PBM in PSS 
(Multidisciplinary team) 
After implementation of PBM 
No. of patients 52  
Preoperative (≈1 month before surgery) Intraoperative Postoperative 
Restrictive Transfusion Strategy 
Packed RBC Transfusion if Hb < 7 g/dL 
Immunohemotherapy appointement: 
Evaluation of Bleeding/ Thrombotic risk; 
 
Screening for anemia and/or ferropenia  
OPTIMIZATION of Hb if: 
(9 g/dL ≤ Hb ≤ 12 g/dL)  
   OR  
12 g/dL < Hb ≤ 15 g/dL + Ferritin (<60) + 
Transferrin Saturation (TS) (<20%)  
 
Screening of Hemostasis: 
 Platelet Function (Agonists used: ADP; TRAP; 
Ristocetin)  Multiplate analyzer® 
 aPTT; PT; Fibrinogen  Coagulometric assays 
 
Intraoperative infusions: 
Tranexamic Acid : 
 Bolus 20 mg/Kg bolus (prophylactic); 
 Continuous Infusion (IV) 10 mg/Kg per hour during 
surgery.  
 
Prophylaxis or therapy of haemorrhagic diatheses:  
 Desmopressin (DDAVP) – 0.3 µg/Kg : 
 30 min before surgery if platelet dysfunction; 
 
 
 
Fibrinogen (Fib.) and ROTEM test during surgery: 
 20-30 mg/Kg if Fib. < 2 g/dL. 
 
Specific Coagulation Factors if necessary; 
 
  
METHODS 
At least 2 Agonists Decreased 
RESULTS 
CONCLUSIONS 
Evaluation: 
 Hemoglobin –   after surgery ( during the first 24 
hours); 
 
 Length of stay at Pediatric Intensive Care Unit (PICU) 
(days). 
 
  
2016-2017 2013-2015 
 
No. of patients=52  
Median Age ≈12.5 years  
 
No. of patients=59  
Median Age ≈ 13.5 years  
        /       (55%/45%) 
PBM Program 
        /       (31%/69%) 
Scoliosis Etiology (%) 
Idiopathic – 47% 
Neuromuscular – 12% 
 Iron suplementation 
 No. of patients 40 (oral intake or IV); 
 Mean dose (oral intake) = 4 mg/Kg; 
 Mean dose (IV administration - Ferric carboxymaltose 
and iron sucrose)=20.08 mg/Kg and 9.3 mg/Kg; 
 
 Impairment of Platelet Function  
 No. of patients: 8 (DDAVP prophylaxis); 
 
 Administration of Factor Concentrates 
 No. of patients: 1 – Administration of coagulation FVII 
concentrate. Comparison 
Preoperative Hb (median g/dL) 13.2 13.4 
Postoperative Hb (median g/dL) 9.3 10.0 
Number of packed RBCs transfused 
(median) 
2 0 
Length of Pediatric Intensive Care 
Unit admission (median days) 
3.06 1.85 
2013-2015 2016-2017 
Scoliosis Etiology (%) 
Idiopathic – 67% 
Neuromuscular – 33% 
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Clinical Case  
Female Patient; 18 years old 
Idiopathic Scoliosis 
Submitted to SS in 2016 
 
